Actavis PLC (NYSE:ACT)

265.39
Data as of Dec 19
 +1.64 / +0.62%
Today’s Change
161.92
Today|||52-Week Range
272.75
+57.97%
Year-to-Date
Corporate Review: A year to remember
9:05am / FT.com
3 Stocks That Might Slash Their Dividends in 2015
Dec 14 / MotleyFool.com
Top Pharmaceutical Stocks to Buy for 2015
Dec 20 / MotleyFool.com
It's Not the Zombie Apocalypse, but Killer Superbugs Could Be on the Way
Dec 14 / MotleyFool.com
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Dec 19 / MotleyFool.com
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Dec 12 / Zacks.com
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Dec 18 / Zacks.com
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog
Dec 11 / Zacks.com
Ackman: Allergan Is A Good Merger Arbitrage Play, Potential 28% Upside
Dec 18 / Benzinga
Mylan Among First to Launch Generic Celebrex - Analyst Blog
Dec 11 / Zacks.com
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Dec 17 / Zacks.com
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Dec 11 / Zacks.com
Alexion Announces New Share Repurchase Program of $500M - Analyst Blog
Dec 16 / Zacks.com
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
Dec 10 / Zacks.com
Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog
Dec 16 / Zacks.com
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Dec 10 / Zacks.com
Sophiris Plunges on Disappointing Data on its BPH Candidate - Analyst Blog
Dec 16 / Zacks.com
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog
Dec 08 / Zacks.com
Billionaires Are Loading Up On These 3 Stocks
Dec 16 / MotleyFool.com
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog
Dec 08 / Zacks.com
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of A...
Dec 16 / Benzinga
Superbug threat drives $9.5bn Merck deal
Dec 08 / FT.com
ChemoCentryx Up on Positive Diabetic Nephropathy Data - Analyst Blog
Dec 15 / Zacks.com
Is It Time to Buy This Growth Stock?
Dec 08 / MotleyFool.com
Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015
Dec 15 / TheStreet.com
Allergan deal sits well on Actavis chief's 'Monopoly board'
Nov 21 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.